We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+2.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.87B
AUM Growth
-$718M
(-28%)
Cap. Flow
-$858M
Cap. Flow
% of AUM
-45.75%
Top 10 Holdings %
Top 10 Hldgs %
41.84%
Holding
112
New
12
Increased
13
Reduced
41
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Glaukos
GKOS
|
+$30.8M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
+$26.9M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$19.7M |
| 4 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$17.7M |
| 5 |
McKesson
MCK
|
+$13.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$49.3M |
| 2 |
Elevance Health
ELV
|
+$43.6M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$41.3M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$36.8M |
| 5 |
Centene
CNC
|
+$36.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.91% |
| 2 | Financials | 1.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
| $190M | 10.12% |
2,308,130
+71,429
| +3% | +$5.36M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $107M | 5.7% |
8,998,413
-1,946,575
| -18% | -$24.2M |
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $96.1M | 5.13% |
3,833,330
+89,179
| +2% | +$2.21M |
|
4
Gilead Sciences
GILD
$167B
| $66.4M | 3.54% |
938,515
-264,485
| -22% | -$17.6M |
|
|
5
CALL
Gilead Sciences
GILD
$167B
| $53.1M | 2.83% |
+750,000
| New | +$49.9M |
|
6
Viatris
VTRS
$20.1B
| $53.1M | 2.83% |
1,367,119
-675,105
| -33% | -$25.9M |
|
|
MNK
7
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $52.8M | 2.82% |
1,178,605
+449,656
| +62% | +$19.7M |
|
|
8
McKesson
MCK
$98.5B
| $51.9M | 2.77% |
315,417
+86,417
| +38% | +$13.1M |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
| $50.5M | 2.69% |
961,147
+165,404
| +21% | +$7.7M |
|
|
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
| $40.3M | 2.15% |
3,655,494
-417,315
| -10% | -$4.19M |
|
|
11
Glaukos
GKOS
$9.21B
| $37.1M | 1.98% |
894,551
+714,551
| +397% | +$30.8M |
|
|
GWPH
12
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $36.1M | 1.92% |
359,983
-65,562
| -15% | -$7.06M |
|
|
XENT
13
DELISTED
Intersect ENT, Inc
XENT
| $33.2M | 1.77% |
+1,189,577
| New | +$26.9M |
|
|
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
| $33.1M | 1.76% |
1,729,268
+325,615
| +23% | +$5.2M |
|
|
LCI
15
DELISTED
Lannett Company, Inc.
LCI
| $31.1M | 1.66% |
380,989
-82,485
| -18% | -$7.19M |
|
16
Editas Medicine
EDIT
$457M
| $28.7M | 1.53% |
1,709,400
| – | – |
|
|
NVRO
17
DELISTED
NEVRO CORP.
NVRO
| $28M | 1.49% |
376,308
-26,690
| -7% | -$2.14M |
|
|
DBVT
18
DBV Technologies
DBVT
$870M
| $23.8M | 1.27% |
66,520
-107,803
| -62% | -$36.8M |
|
|
PTLA
19
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $23.5M | 1.26% |
419,000
-1,032,301
| -71% | -$41.3M |
|
20
Cartesian Therapeutics
RNAC
$243M
| $21.1M | 1.12% |
35,333
| – | – |
|
|
SYRS
21
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $20.4M | 1.09% |
126,895
-34,619
| -21% | -$5.44M |
|
|
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
| $20.1M | 1.07% |
251,167
-502,133
| -67% | -$27.8M |
|
|
AET
23
DELISTED
Aetna Inc
AET
| $19.7M | 1.05% |
130,000
-137,000
| -51% | -$19.4M |
|
24
BioCryst Pharmaceuticals
BCRX
$2.36B
| $19.5M | 1.04% |
3,499,202
+413,966
| +13% | +$2.52M |
|
|
PDCO
25
DELISTED
Patterson Companies, Inc.
PDCO
| $18.5M | 0.98% |
+393,262
| New | +$17.7M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2017 Portfolio in Review
As of Q2 2017, Deerfield Management held 112 positions worth $1.87B, down 28% from $2.59B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management withdrew a net $858M in Q2 2017, closing 27 positions and reducing 41 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 71% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Intersect ENT, Inc worth $33.2M.
- Deerfield Management's largest Q2 2017 buy was Intersect ENT, Inc: 1,189,577 shares worth $33.2M.
- Deerfield Management added most to Glaukos in Q2 2017, an estimated $30.8M increase.
- Deerfield Management's biggest Q2 2017 reduction was Blueprint Medicines, cutting an estimated $49.3M.
- Deerfield Management fully exited Vanda Pharmaceuticals in Q2 2017, selling an estimated $32.2M.
- Deerfield Management's ten largest holdings make up 42% of its $1.87B portfolio in Q2 2017.
- Deerfield Management opened 12 new positions and closed 27 in Q2 2017.
- Deerfield Management's portfolio value fell 28% quarter-over-quarter to $1.87B.
Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.